Menu ×

Dengue Vaccines To Help Lower Incidences of Dengue Virus – Global Dengue Vaccine Market is Anticipated To Grow With a CAGR of Around 22% Throughout 2019-2027

  • Text Size:

Research Nester has released a report titled Dengue Vaccine Market – Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global dengue vaccine market in terms of market segmentation by age group, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The global dengue vaccine market is segmented by age group into <6 years, 6-12 years and >12 years, out of which, >12 years segment is anticipated to hold the largest market share of around 54% in the year 2027 and cross nearly USD 680 million by the end of 2027. The segment is further anticipated to grow with a significant CAGR over the forecast period, i.e. 2019-2027. Additionally, the <6 years segment is estimated to grow with the highest CAGR of around 22% over the forecast period.

The global dengue vaccine market is anticipated to achieve a CAGR of around 22% during the forecast period. Growing concern for dengue diseases as well as the clinical advancements observed in the development of vaccines for dengue are some of the factors anticipated to contribute significantly towards the growth of the global dengue vaccine market. Further, the global dengue vaccine market is predicted to cross a value of USD 1100.0 million by the end of 2027.

Regionally, the global dengue vaccine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Among these regions, Asia Pacific is anticipated to hold the largest market share of around 30% share in the year 2027 owing to the numerous number of outbreaks in the region that has occurred over the years along with the need to take large quantity of dengue vaccines by the government to treat the disease are some of the factors anticipated to drive the growth of the global dengue vaccine market in the region. Additionally, the dengue vaccine market in Latin America is anticipated to grow significantly over the years, especially in nations such as Brazil, Mexico and Rest of Latin America, as these regions are prone to the disease on the back of the tropical environment of the region.

Growing Incidences of Dengue Disease

In the statistics by the World Health Organization (WHO), it estimated that around 100-400 million dengue infections occur each year around the globe and that half of the world’s population is now at risk. Moreover, in the last two decades, there has been an increase by over fifteen-fold in the total number of dengue cases reported to the WHO, reaching a total up to 3,312,040 numbers in the year 2015.

Growing concern for the increasing cases of dengue disease around the world is raising the necessity of individuals and governments to adopt dengue vaccine as a precursor measure to the cure of the disease, which is considered as a major factor driving the growth of the global dengue vaccine market. With concerns of several under-developed and developed nations for the spread of the disease, governments are increasingly investing on research and development activities as well as to purchase the vaccine, which is also lowering the cost of the vaccine. The lowered cost raises the chances of greater adoption of the vaccine which is also anticipated to drive the growth of the global dengue vaccine market in the coming years.

However, concerns regarding low awareness amongst individuals and governments of several nations for the availability of the dengue vaccine is anticipated to limit the growth of the global dengue vaccine market.

This report also provides the existing competitive scenario of some of the key players of the global dengue vaccine market, which includes company profiling of Merck & Co., Inc. (NYSE: MRK), Sanofi (EPA: SAN), GlaxoSmithKline plc (LON: GSK), Takeda Pharmaceutical Company Limited (TYO: 4502) and Institut Pasteur. Moreover, numerous players are also increasingly investing on research and development activities for the launch of advanced form of dengue vaccines. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global dengue vaccine market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved